The clinical presentation of Hodgkin\u27s disease with liver involvement by Urbano, Anthony Michael
Yale University
EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library School of Medicine
1981




Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.
Recommended Citation
Urbano, Anthony Michael, "The clinical presentation of Hodgkin's disease with liver involvement" (1981). Yale Medicine Thesis Digital
Library. 3266.
http://elischolar.library.yale.edu/ymtdl/3266
YALE MEDICAL LIBRARY 
3 9002 08676 2656 
THE CUNiCAL PRESENTATION OF HODGKIN'S 
disease with liver involvement 
ANTHONY MICHAEL URBANO 
; -t.. --. 

Digitized by the Internet Archive 
in 2017 with funding from 





The Clinical Presentation of Hodgkin's 
Disease With Liver Involvement 
A thesis submitted to the Faculty of Yale University School of 
Medicine in partial fulfillment of the requirement for the degree 
of Doctor of Medicine 





I would like to express my sincere appreciation to my thesis 
advisor, Dr. Edwin Cadman for his valuable suggestions, support 
and encouragement during the preparation of this thesis. I would 
also like to thank Mary Nordlund for her aid in obtaining medical 
records and Hillary Raeffer for her excellent secretarial assistance. 

TABLE OF CONTENTS 
Paqe 
I. Introduction. 1 
II. Materials and Methods . 2 
III. Results. h 
IV. Discussion. 28 
„ _ 39 
V. References 

LIST OF TABLES 
Pages 
1. Age distribution of patients with liver involvement vs. controls. 10 
2. Sex distribution of patients with liver involvement vs. controls. 11 
3. Histological distribution of patients with liver involvement 
vs. controls. ^ 
4. Age-histological distribution of patients with liver involvement vs 
controls. 13 
5. Evidence of splenic or marrow involvement at onset. 14 
6. Symptoms at presentation. 15 
6a. Symptoms at presentation - details. 16 
7. Physical signs at presentation. 17 
7a. Physical signs at presentation - details. 18 
8. Radiological evidence of disease at presentation. 19 
8a. Liver-spleen scans in patients with liver involvement vs controls. 20 
8b. Comparison of liver-spleen scans with lymphangiograms. 21 
9. Laboratory evidence of disease at presentation. 22 
9a. Laboratory values of patients with liver involvement-LFT's, serum 
23 
protein electrophoresis, and CBC with differentials. 
24 
10. Survival... 
11. Age distribution of patients with liver involvement who has 
survived vs controls. ^ 
27 
12. Survival curve. 

LIST OF FIGURES 
Pages 
1. Hodgkin's Disease Chemotherapy Program...5 
2. The Overall Treatment Program.5 
3. Survival Curve of Patients with Liver Involvement.26 

Introduction 
The incidence of liver involvement with Hodgkin's disease has 
been reported to occur in 5 to 11% of cases at the time of staging 
laparotomy (1-4). 
At the time of presentation liver involvement is often suspected 
on the basis of abnormal physical findings, such as hepatomegaly, 
abnormal radiological isotopic scans, or abnormal liver function 
tests. Ultimately confirmation of hepatic disease is dependent 
on the more reliable wedge liver biopsy as opposed to percutaneous 
needle biopsy. This is done under direct visualization during 
laparotomy. 
At Yale from 1969 to 1980, sixteen patients presented with 
Hodgkin's disease with liver involvement. These patients were 
all part of a protocol study involving 146 patients with stage 11 IB 
and IV Hodgkin's disease. Of interest was how in particular did 
they present clinically; specifically, in terms of basic epidem¬ 
iology of age, sex, histology and by signs, symptoms and results 
of radiological and laboratory tests. Also of interest is whether 
a combination of clinical evidence can be considered reliable 
enough to presume liver involvement without laparotomy and wedge 
biopsy. 
In this study the above clinical parameters were compared with 
those presenting in a carefully chosen control group of patients 
within the same protocol study who have essentially similar extent 
of disease except for biopsy-negative livers. 

Materials and Methods 
Patients 
The members of this study were among 146 patients in a sequential 
combination chemotherapy-radiotherapy program in the management 
of stage 11 IB and IV advanced Hodgkin's disease. This study was 
conducted at Yale University School of Medicine - Yale-New Haven 
Hospital by the Departments of Medicine and Radiotherapy. It 
attempted to define the ability of combination drug therapy to 
induce complete remissions and the value of subsequent radiothera¬ 
py in prolonging remission duration and overall survival. 
All patients were staged according to the Ann Arbor Staging 
Classification. Patients considered suitable for combined modal¬ 
ity therapy were those who were newly diagnosed with stage 11 IB or 
IV disease at presentation or those who had relapsed following 
initial radical radiotherapy. Staging procedures included the 
usual blood studies, chest x-ray and tomograms, lymphangiograms 
99 
and intravenous pyelogram, gallium and technetium liver-spleen 
scans, bone marrow aspirate and biopsy, and in some instances liver 
biopsy. Among the relapsed patients, biopsy confirmation of re¬ 
current disease was required unless there was unequivocal radio¬ 
logical evidence of Hodgkin's disease. 
All patients being treated in this protocol received chemotherapy 
first according to the timetable in Figure 1. Prednisone was given 
in a dose of 40mg/square meter for the first 3 weeks of the cycle, 
and then tapered off over the next 2 weeks of the cycle. A maxi¬ 
mum amount of 2.2mg of Vincristine was used. Drug dosage was re- 
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duced depending on the patients' peripheral blood status, degree 
of neurotoxicity, and gastrointestinal reaction. 
The overall treatment program is schematically represented in 
Figure 2. Three cycles of drugs were given, each cycle lasting 
approximately 6 weeks and followed by a 2 week rest interval. 
Prednisone was ommitted from the second cycle. One month fol¬ 
lowing the completion of the third cycle, remission status was 
fully assessed. A complete remission was defined as the absence 
of all clinical, radiographic and laboratory evidence of disease. 
Complete responders were then treated with low dose radiotherapy 
to the anatomic areas known to have been involved with Hodgkin's 
disease before the institution of chemotherapy - with the excep¬ 
tion of the bone marrow. Radiation treatments were delivered with 
either a 6-MeV or 4-MeV linear accelerator or cobalt - 60 machine. 
The doses used were 1,500-2,500 rads at a dose rate of 800-1,000 
rads per week. Patients with hepatic involvement received whole 
liver irradiation at rates of 150 rads per treatment with total 
dosage not exceeding 2,000 rads. If more than one radiation field 
was necessary and the fields were large, a 2-3 week rest period 
between treatments was allowed for bone marrow recovery. 
Following radiotherapy, there was a rest period of 3-4 weeks and 
then two additional drug cycles were given. Prednisone was ommitted 
from the fourth cycle. All treatment was stopped at the comple¬ 
tion of the fifth cycle (14-18 months of total treatment time). 
Annual reevaluation included repeat lymphangiograms, appropriate 
x-rays, scans and biopsies to access remission status. 
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The present study compared two groups of patients within the 
aforementioned combined modality therapy protocol. Group 1 con¬ 
sisted of 16 patients with biopsy proven liver involvement with 
Hodgkin's disease at the time of their presentation with disease. 
Group 2 (control group) consisted of 12 patients with stage III 
or IV Hodgkin's disease. All group 2 patients had laparotomies 
with biopsy-negative livers. Five of these patients also had 
biopsy-negative spleens. Tables 1-3 depicts the distribution 
of age, sex, and histology among these two groups. 
Study Design 
The medical records of patients in groups 1 and 2 were reviewed. 
A comparison was made between the two groups regarding age, sex, and 
histological distribution, evidence of splenic and marrow involvement 
at presentation, signs, symptoms, radiological and laboratory 
evidence of disease and survival. 
Statistical Analysis 
Chi-square test was used to determine the significance of dif¬ 
ferences between proportions. The Yates' correction was employed 
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The Overall Treatment Program 
3 5 7 9 
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* Designed by Alan F. Bloom '83, Yale Medical School 




Over the past ten years sixteen patients presented to Y-NHH with 
biopsy proven liver involvement with Hodgkin's disease. A study 
of their presentation and comparison with a control group is made. 
The age distribution of liver patients is 44% under 30 yrs. old 
and 56% over 30 yrs. old. In the control group the distribution 
was 66% and 33% respectively (Table 1). The difference in dis¬ 
tribution between the two groups isn't statistically significant. 
The sex distribution of liver patients is males, 62%; females 38%. 
In the control group the distribution is males 58%; females 42% 
(Table 2). 
The histological distribution of liver patients is nodular 
sclerosis, 25%; mixed cellularity, 50%; lymphocyte predominant, 
6%; and lymphocyte depleted, 19%. In the control group the dis¬ 
tribution was 58%, 33%, 0%, and 9% respectively (Table 3). The 
difference in distribution between the two groups isn't statistically 
significant. 
The age-histological distribution of liver patients is for 
those less than 30 years old-nodular sclerosis 25%; mixed cellu¬ 
larity 6%; lymphocyte predominant 6%; and lymphocyte depleted 6%. 
The respective data for those over 30 are 0%, 44%, 0% and 12%. 
Within the control group, the distribution for those less than 
30 is, nodular sclerosis 50%; mixed cellularity 17%; and lympho¬ 
cyte predominant and depleted 0% each. The respective data for 
those over 30 are 8%, 17%, 0% and 8% (Table 4). Of note is that 
the age-histological distribution of liver patients with nodular 
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sclerosis and mix cellularity histologies were statistically sig¬ 
nificant as were the distribution of control patients with lympho¬ 
cyte predominant histology. The age-histological distribution 
of liver patients over 30 yrs. old with lymphocyte predominant 
histology versus a similar control group was statistically sig¬ 
nificant. The above were all significant at the 95% confidence 
level. 
Evidence of splenic involvement at presentation in liver pa¬ 
tients occurred in 81% of the cases. This was assessed by biopsy 
at laparotomy, abnormal spleen scan or evidence of splenomegaly 
by physical exam. Evidence of marrow involvement, assessed by 
aspiration and biopsy, at presentation in liver patients occurred 
in 38% of cases. The respective data among control patients were 
50% with splenic involvement and 8% with marrow involvement (Table 5). 
The distribution of splenic and marrow involvement in liver pa¬ 
tients versus controls wasn't statistically significant. B sym¬ 
ptoms of weight loss, or fever with or without night sweats were present 
in 88% of 1 iver patients at the time of their presentation with 
Hodgkin's disease while these symptoms occurred in 67% of the 
control patients (Table 6). A breakdown of these symptoms is 
shown in Table 5a. The difference between these two groups wasn't 
statistically significant. 
The physical signs at presentation of Hodgkin's disease among 
patients with liver involvement and controls is depicted in Tables 
7 and 7a. Hepatomegaly, splenomegaly or both were present in 
87% of liver patients as compared with 8% in the controls. The 
difference between these groups was statistically significant (pc.OOOl). 
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The radiological evidence of Hodgkin's disease at the time of 
presentation is shown in Tables 8, 8a and 8b. Among the patients 
with liver involvement 93% and 92% presented with abnormal liver- 
spleen scans and lymphangiograms respectively. While only 25% and 
75% had abnormal liver-spleen scans or lymphangiograms respectively 
among the controls. Also 69% of the patients with liver involve¬ 
ment had both abnormal liver-spleen scans and lymphangiograms at 
presentation while 6% had abnormal liver-spleen scans with normal 
lymphangiograms. 
As depicted in Table 8 the difference in distribution of re¬ 
sults of liver-spleen scans in liver patients and controls is statis¬ 
tically significant (p<_ .0001) while the difference wasn't statis¬ 
tically significant regarding the results of lymphangiograms. 
Laboratory evidence of disease at presentation is depicted in 
Tables 9 and 9a. Among the patients with liver involvement 94% 
had abnormal liver function tests (LFT's), 77% had abnormal albumin- 
globulin profiles, and 66% had anemia. In comparison, among the 
controls only 33% had abnormal LFT's, 0% had abnormal albumin-glo¬ 
bulin profiles and 33% had anemia. The difference between liver 
patients and controls was statistically significant regarding LFT's 
and albumin-globulin profile (p<_.0001) while the difference re¬ 
garding anemia wasn't. 
In Table 10, is depicted the survival of the patients studied 
with liver involvement compared with that of the controls. Among 
the patients with liver involvement 50% are still alive while 
100% of the controls are still living. This difference is statis¬ 
tically significant (p<_.0001). 
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The age distribution of patients with Hodgkin's disease and liver 
involvement who has survived without evidence of disease compared 
to controls is shown in Table 11. Those survivors over 30 years 
of age among the liver patients versus controls comprise 44% and 100% 
respectively. This difference is not statistically significant. 




AGE DISTRIBUTION OF PATIENTS WITH LIVER 
INVOLVEMENT VS. CONTROL 
Liver Control 
Age-Yrs No. % of Total No. % of Total 
10-29 7 44% 8 66% 
30-59 9 56% 4 33% 
Total 16 100% 12 100% 





SEX DISTRIBUTION OF PATIENTS WITH LIVER 
INVOLVEMENT VS. CONTROLS 
Liver Control 
Male 10 62% 7 58% 
Female 6 38% 5 42% 




HISTOLOGICAL DISTRIBUTION OF PATIENTS WITH 
LIVER INVOLVEMENT VS. CONTROLS 
Liver Control 
No. % of Total No. / o of Total 
Nodular Sclerosis 4 25% 7 58% 
Mixed Cellularity 8 50% 4 33% 
Lymphocyte Predominant 1 6% 0 0% 
Lymphocyte Depleted 3 19% 1 9% 
Total 16 100% 12 100% 





AGE-HISTOLOGICAL DISTRIBUTION OF PATIENTS WITH 
LIVER INVOLVEMENT VS. CONTROLS 
Liver Controls 
10- -29 vrs. 35- 59yrs. 10- 29 yrs. 30- 59yrs. 
No. % of No. % of No. % of No. % of 
Total Total Total Total 
Nodular Sclerosis 4 25% 0 0% 6 50% 1 8% 
Mixed Cellularitv 1 6% 7 44% 2 17% 2 17% 
Lymphocyte Predominant 1 6% 0 0% 0 0% 0 0% 
Lymphocyte Depleted 1 6% 2 12% 0 0% 1 8% 
Total 7 43% 9 56% 8 67% 4 33% 
The Age-histologv distribution of NS and MC - hepatic involved pts. were 
statistically significant, as were the age-histology distribution of LP- 
control patients. The age-histology distribution of LP-HD patients 30-5 9 
yrs. old with Hepatic involvement vs. controls were statistically signi¬ 




EVIDENCE OF SPLENIC OR MARROW INVOLVEMENT 
AT ONSET 
Liver 
No. % of Total 
Control 
No. % of Total 
w/splenic involvement* 13 81% 6 50% 
w/o splenic involvement** 3 9% 6 50% 
Total 16 100% 12 100% 
w/marrow involvement 6 38% 1 8% 
w/o marrow involvement 10 62% 11 92% 
Total 16 100% 12 100% 
* 8 of the 13 patients with liver involvement had biopsy-proven splenic in¬ 
volvement as well. The remaining 5 had both abnormal spleen scans and spleno¬ 
megaly suggesting HD-involvement without biopsy confirmation. Also all 12 
control patients had laporotomies and splenectomies with pathological assessment 
of HD-involvement. 
case 1 - no pathological, radiological or clinical data regarding spleen in 
medical record. 
case 2 - spleen was removed w/o HD involvement prior to current presentation 
in relapse with liver involvement. 
case 3 - splenic enlargement noted during exploratory laporotomy without 
pathological specimen of spleen taken. 
3 by marrow asp/bx 
Distribution of evidence of splenic and marrow involvement in hepatic in¬ 




SYMPTOMS AT PRESENTATION 
Liver Control 
No. % of Total No. % of Total 
B symptoms-*- 14 88% 8 67% 
w/o B symptoms 2 12% 4 33% 
Total 16 100% 12 100% 
wt. loss, fever with or without night sweats. 
Distribution of B symptoms in hepatic involved patients vs. controls 





CONSTITUTIONAL SYMPTOMS AT PRESENTATION-DETAILS 
Liver Control 
Asymptomatic 1 4 
Pruritus Only 1 0 
Fatigue 0 0 
Weight Loss 3 1 
Fever Only 0 0 
Fever w/Nite Sweats 1 4 
Fever w/Nite Sweats & Weight 
Loss 
10 3 




PHYSICAL SIGNS AT PRESENTATION 
Liver_ Control 
No. % of Total No. % of Total 
Adenopathy 2 12% 11 92% 
Hepatomegaly, Splenomegaly 
or both 
14 87% 1 8% 
Total 16 100% 12 100% 
Distribution of physical signs of hepatic involved patients vs. controls 




PHYSICAL SIGNS AT PRESENTATION-DETAILS 
Liver Control 
Peripheral Adenopathy Only 2 11 
Hepatomegaly 2 0 
Splenomegaly 4 1 
Hepatosplenomegaly 8 0 




RADIOLOGICAL EVIDENCE OF DISEASE AT PRESENTATION 
Liver Controls 
No. % of Total No. % of Totals 
Normal Liver-Spleen Scans 1 7% 6 75% 
Abnormal Liver-Spleen Scans 13 93% 2 25% 
Total 14 100% 8 100% 
Normal LAG 1 8% 3 25% 
Abnormal LAG 12 92% 9 75% 
Total 13 100% 12 100% 
Distribution of L/S scan results of hepatic involved patients vs. con¬ 
trols was statistically significant at the .01% confidence level, while 




LIVER-SPLEEN SCANS IN PATIENTS WITH LIVER 
INVOLVEMENT VS. CONTROLS 
Liver Controls 
No. % of Total No. % of Total 
Normal L/S Scan 1 6 
ILiver w/o Focal Defects 2* 0 
ILiver w/ Focal Defects 0 0 
ISpleen w/o Focal Defects 0 2 
iSpleen w/ Focal Defects A 0 
+L/S w/o Focal Defects 3 0 
1L/S w/ Focal Defects A 0 
Total 1A 8 
* 1 patient had splenectomy prior to presentation with liver involvement. 




COMPARISON OF LIVER/SPLEEN SCANS W/LYMPHANGIOGRAM 
Liver Control 
No. % of Total No. % of Total 
Both abnormal L/S scan and 
Lymphangiogram 
11 69% 2 16% 
Abnormal L/S Scan w/normal 
LAG 
1 6% 0 0% 
Normal L/S scan w/abnormal 
LAG 
1 6% 5 42% 
Both normal L/S scan and 
Lymphangiogram 
0 0% 0 0% 
Without L/S scan or LAG 3 19% 5 42% 




LABORATORY EVIDENCE OF DISEASE AT PRESENTATION 
Liver Control 
No. % of Total No. % of Total 
Normal LFT's 1 6% 10 67% 
Abnormal LFT's 15 94% 2 33% 
Total 16 100% 12 100% 
Normal Albumin/Globulin 
Profile 2 23% 4 100% 
Abnormal Albumin/Globulin 7 77% 0 0% 
Profile 
Total 9 100% 4 100% 
Anemia 8 67% 4 33% 
w/o anemia 4 33% 8 67% 
Total 12 100% 12 100% 
Distribution of LFT’s and A/G in hepatic involved pts. vs. controls were 
statistically significant the 99.99% confidence level, while distribution 














E. A. iLDH N.I. Normal 









G.I. tCephlatin Flocculation 
Thymol Turbidity 
A4-GL Normochronic,Normocytic Anemia 
Neutropenia,Lymphocytosis 
R.W. ILDH,Aik Phos,SGOT, 
Bilirubin,5'Noc,Cu 
PT,Thymol Turbidity 
AIG1 f^jglobulin Normochronic,Normocytic Anemia 
Neutropenia,Lymphopenia,Trombo- 
cytopenia,Monocytosis 
R.K. Normal Normal Normal 
J.W. ISerum Cu A1G+ lcc2gl°t,ulin Normal 
M.D. "abnormal LFT's" N.I. N.I. 
F.L. +Aik Phos,LDH,SGOT, 
PT 
AlGt Normochronic,Normocytic Anemia 
Granulocytosis,Lymphopenia 
C.D. fBSP,Aik Phos,Bilirubin AlGi Hypochronic,Microcytic Anemia 
Granulocytosis,Lymphopenia 
J.M. +Alk Phos,SGOT,PT,PTT, 
BSP 
Normal Anemia w/o Indices Neutropenia 
Lymphocytosis 
J.B. "abnormal LFT’s" N.I. N.I. 
L.R. "abnormal LFT's" N.I. N.I. 
P.F. "abnormal LFT's" A1G1 f^globulin Hypochronic Microcytic Anemia 
S.O. 1BSP N.I. Granulocytosis,Lymphocytosis 
M.S. lAlk Phos. N.I. N.I. 






No . % of Total No. % of ' 
Alive * 8 50% 12 100% 
2 
Deceased 8 50% 0 0% 
Total 16 100% 12 100% 
Distribution of survival of hepatic involved patients vs. controls was statistically 
significant at the 99.99% confidence level. 
^ with no evidence of Hodgkin’s disease. 




AGE DISTRIBUTION OF PATIENTS WITH LIVER 
INVOLVEMENT WHO HAS SURVIVED VS. CONTROLS 
Liver Control 
No. % Alive No. % Alive 
10-29 4 57% 8 100% 
30-59 4 44% 4 100% 
Total 16 12 











Response No. A1 ive 
None 3 0 
Partial 5 1 
Complete 8 7 
4 
- ^—,-— 1.—r- 







Years Followup No. Response to Chemotherapy 
0-1 5 (all DWD*) 3- No Response 
2- Partial Response 
1-5 3 2- Partial Response - both DWD 
1- Complete Response 
(diagnosed <5 years ago; still 
alive) 
5-10 4 3- Complete Response - 1 DWD 
(1 with radiation Tx failure to 
mediastinum; still alive) 
1- Partial Response 
(with radiation Tx failure in Rt 
axilla; still alive) 
10 4 4- Complete Response 
Total 16 




The present study attempts to review the presentation of advanced 
Hodgkin's disease patients with liver involvement. 
Liver involvement with Hodgkin's disease showed no particular age 
predilection being approximately equally distributed above and below 
30 yrs. of age. Studies of age-specific incidence of Hodgkin's 
disease by MacMahon (5) and, in particular, in Connecticut by Correa 
and O'Conor (6) suggest a bimodal distribution of approximately 
equal magnitude centering around 40 yrs. This suggests that pa¬ 
tients presenting with Hodgkin's disease and liver involvement 
have similar age-specific incidences as Hodgkin's disease in general. 
Hodgkin's disease is more prevalent in males than in females. 
A male-female sex ratio ranging from 1.38 to 1.94 has been cited; 
not changing appreciably from data as far back as 1911 (7). 
Patients with liver involvement in our study revealed a similar 
predominance with a male-female sex ratio of 1.63 compared to 
the control groups ratio of 1.38. 
The histological breakdown of Hodgkin's disease has been var¬ 
iously reported as nodular sclerosis approximately 50%; mixed cellu- 
larity about 40% and lymphocyte predominant and depleted each 
about 5% respectively. The distribution among our liver patients 
is distinct but the number in our study is too small to draw sta¬ 
tistically significant inference in comparison to the general pop- 
ulationof Hodgkin's cases. Nevertheless, it is of interest to 
note that among our patients with liver involvement, the most 
common histopathologies were mixed cellularity and nodular sclerosis 
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and the least common was lymphocyte predominant. This would be pre¬ 
dicted based on studies by Kadin, Glatstein and Dorfman (8) and 
Dorfman (9) who showed that the predominance of patients with para¬ 
aortic and splenic involvement had histologic diagnosis which were 
most commonly mixed cellularity and nodular sclerosis. Furthermore 
the predominance of clinical stage III and IV were among those 
patients with mixed cellularity and nodular sclerosis as histologic 
diagnosis while most patients with stage I were confined to lym¬ 
phocyte predominant cases. In addition, vascular invasion of the 
spleen was shown by Kirschner et.al. (10) to be important in wide¬ 
spread dessemination. In his study he showed that vascular invasion 
in 16% of 44 spleens examined at laparotomy were associated with 
dissemination to the liver and bone marrow. In Rappaport and 
Strum's study (11) the percentage incidence of vascular invasion 
per histological type was found to be lymphocyte depleted 43%, 
mixed cellularity 3%, nodular sclerosis 8%, and lymphocyte pre¬ 
dominant 0%. If one were to consider the prevalence of each his¬ 
tological type of Hodgkin's disease in the general population and 
multiply it by the % incidence of vascular invasion per each his¬ 
tological type as estimated by Rappaport and Strum one may get a 
distribution of histological types in patients with liver involve¬ 
ment which might approximate our results in Table 3. 
The age-histological distribution of patients with liver involve¬ 
ment and histologies of either nodular sclerosis or mixed cellularity 
was statistically significant as is shown in Table 4. Patients with 
nodular sclerosis were predominantly under 30 and those with mixed 
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cellularity were over 30. This is in general agreement with the age- 
histological distribution of Hodgkin's patients studied by Keller 
et.al. (12) which revealed a peak in the 15 to 25 year age range 
for nodular sclerosis, whereas the peak for mixed cellularity appears 
to occur distinctly later between 25 and 45 years of age. This sug¬ 
gests that for those Hodgkin's disease patients presenting with 
liver involvement and with histologies of mixed cellularity or 
nodular sclerosis their age distribution were no different than those 
of Hodgkin's disease patient in general. 
It is generally held that Hodgkin's disease progresses via con¬ 
tiguous spread of lymphatic chains. The spleen is involved via lym¬ 
phatic spread and within the spleen vascular invasion occurs and it 
is by the blood that the liver subsequently becomes involved. In 
over 800 diagnostic laparotomies reviewed by Kaplan there has been 
no instance of liver involvement without concomitant splenic in¬ 
volvement. This is supported by our data in Table 5. Therefore it 
was questioned whether clinical evidence of splenic involvement would 
be fairly reliable evidence of liver involvement as well. As can be 
appreciated by Table 5, although a preponderance of patients with liver 
involvement presented with clinical evidence of splenic involvement, 
50% of the control patients presented with clinical evidence of splenic 
involvement as well either by biopsy, abnormal spleen scan and/or 
evidence of splenomegaly on exam. Also the difference in distribution 
between the liver group and controls were statistically insignificant, 
since there is no difference in the likelihood of having clinical 




patients or controls one can not use this as a criteria for orobable 
hepatic involvement. 
The bone marrow is involved with Hodgkin's disease in from 5-15% 
of previously untreated patients (13). It is generally associated 
with stage III or IV disease. Invariably the spleen is also involved. 
Again because of the suspected close association of splenic and 
hepatic involvement it was questioned what would be the association 
between marrow and liver involvement. As shown in Table 5, the 
marrow was found to be involved in the minority of cases in both 
the liver patients and controls, the distribution between the 
two groups being statistically insignificant. Therefore evidence 
of marrow involvement cannot be used as strong suggestive evidence 
of hepatic involvement. 
It is well established that constitutional symptoms are re¬ 
latively infrequent in stage I cases, predominating in stages III 
and IV. Therefore it was questioned if compared to our control 
group of stage III and IV patients with negative liver biopsies, 
whether patients with liver involvement presented more frequently 
with B symptoms of fever, weight loss, or night sweats. As shown 
in Tables 6 and 6a, the majority of patients in both the study and 
control groups presented with B symptoms; the difference not being 
statistically significant. Consequently it appears that consti¬ 
tutional symptoms is more a function of anatomical extent of disease 
in general. 
Therefore the presence of B symptoms in patients with advanced 
Hodgkin's disease isn't a specific marker for liver involvement. 
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Nevertheless, it is worth noting that 10 patients with liver in¬ 
volvement presented with all 3 B symptoms while only three pa¬ 
tients among the control group presented in such a manner. Also 
4 patients in the control group presented asymptomatically versus 
only one in the study group. This suggests that generally patients 
presenting with liver involvement will most likely have more im¬ 
pressive constitutional symptoms at presentation including quite 
frequently weight loss, fever, and night sweats simultaneously. 
Of particular interest are the physical signs at presentation of 
patients with liver involvement compared to controls. The major¬ 
ity of patients with liver involvement oresented with hepatomegaly, 
splenomegaly or both (87%) compared to only one patient with 
splenomegaly in the control group (8%). Also 92% of patients in 
the control group presented with peripheral adenopathy only com¬ 
pared with 12% among the patients with liver involvement. These 
differences were statistically significant (p<_.0001). Of interest 
is that no patients in the control group presented with either hepa¬ 
tomegaly or hepatosplenomegaly while 12% and 50% respectively 
presented with these signs among the patients with liver involvement. 
Therefore these two signs appear to be fairly reliable indicators 
of liver involvement. 
Liver-spleen scans have been investigated for sometime as diag¬ 
nostic adjuncts in the clinical staging of Hodgkin's disease. 
Lipton et.al. (14) reviewed 49 liver scans but only four cases 
had biopsy proven liver involvement thus limiting the reliability 
of conclusions drawn from that study despite the fact that all four 

33 
cases had abnormal liver scans. Milder et.al. (15) reviewed the 
liver-spleen scans in 108 patients with Hodgkin's disease. Only 
20 patients in this study had biopsy proven liver involvement. Of 
these patients, only 10 demonstrated filling defects or mottled 
uptake on scan. It is presumed that the others were normal al¬ 
though no information was given as to the size of the liver. These 
defects were also present in 25% of biopsy negative livers. Con¬ 
sequently, except for the size of the left lobe, no finding on 
liver scan was concluded to be diagnostic of tumor involvement. 
Although the authors suggest that a combination of results from 
lymphangiogram liver-spleen scans, and physical exam may be used 
to form an index of suspicion for liver involvement which may 
prove useful in avoiding laparotomy, they concluded for the present, 
as did Lipton et.al., that only histiological examination of ade¬ 
quate liver biopsies can be considered definitive evaluation for 
liver involvement. 
The result of our study of liver-spleen scans suggests that 
they may be more useful in the diagnostic workup of liver involve¬ 
ment than previously indicated. Specifically as indicated in Tables 
8 and 8a, 93% of patients with biopsy-positive liver involvement 
presented with abnormal liver-spleen scans whereas only 25% in the 
control group presented with abnormalities. This difference is 
statistically significant. Of note is that of the two control pa¬ 
tients with abnormal liver spleen scans both had only enlarged 
spleens without focal defects. This finding has been commonly 
attributed to reactive hyperplasia secondary to Hodgkin's disease 
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elsewhere. Also every patient with liver involvement who presented 
with an abnormal liver-spleen scan - except for one - had at least 
an abnormal spleen scan. This again; albeit in a rather crude 
fashion gives further support that splenic involvement always pre- 
ceeds liver involvement. 
Among the patients with liver involvement, 92% presented with 
abnormal lymphangiograms while 8°l viere normal. Considering the 
contiguous spread of Hodgkin's disease from nodes to spleen and 
than liver, one can assume that the 8% is a false negative rate 
which is much higher than the 2% false negative rate which is 
usually quoted for lymphangiograms (16). 
A number of investigators have attempted to find some cor¬ 
relation between liver function tests and liver involvement with 
Hodgkin's disease. Glatstein et.al. (17) reviewed the liver func¬ 
tion tests of 29 patients with suspected or biopsy-proven liver 
involvement, they concluded that involvement was not well cor¬ 
related with anyone liver function test. Although abnormalities 
of each liver function test could be demonstrated at one time or 
the other among the several cases, BSP retention and alkaline phos¬ 
phatase tended to be abnormal more frequently. Of the 12 patients 
who had both BSP retention and alkaline phosphatase abnormalities 
only 7 had positive liver biopsies the remainder were biopsy ne¬ 
gative. 
Aisenberg et.al. (18) studied the serum alkaline phosphatase 
levels in 111 patients at the onset of Hodgkin's disease. He found 
that with increasing stages of the disease, there was an increasing 
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percentage of patients with elevated levels of enzymes, for example, 
14% in stage I and 81% in stage IV. Electrophoretic studies of the 
phosphatase revealed that most of the elevated levels were hepatic 
in origin and that this was the source in virtually all of the 
advanced cases. But the association of elevations in stage I cases, 
in cases with negative liver biopsies and being reversible associated 
with fevers, all imply the unreliability of elevated alkaline phos¬ 
phatase as a specific marker of hepatic involvement. The conclusions 
of Aisenberg et.al. were later supported by the work of Belliveau 
et.al. (19) and with the increasing suggestion of non-neoplastic 
hepatic disease presenting concomitantly with Hodgkin's disease 
(20,21) all raised serious questions as to the utility of liver 
function tests for diagnosis of liver involvement. 
More support for the use of liver function tests can be found 
in the result of our study. Of the 16 patients with biopsy-proven 
liver involvement only one patient presented with normal liver 
function tests. As shown in Tables 9 and 9a among the patients 
with liver involvement, 94% presented with abnormal LFT's while 
only 33% of the control patients had abnormal LFT's. This dif¬ 
ference was highly statistically significant (p<_.0001). Table 
9a reveals the wide variety of abnormalities in LFT's. Of note 
is that elevated alkaline phosphatase was the most common ab¬ 
normality and that in several cases only one test was positive. 
This suggests the necessity to use a wide variety LFT's to detect 
potential liver involvement. 
Serum protein abnormalities have been well described in Hodgkin's 
t 
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disease. Arends et.al. (22) and Neely et.al. (23) have demonstrated 
that in Hodgkin's disease, hypoalbuminemia and increased concen¬ 
trations of alpha^, alpha2, and/or beta globulins occurred commonly. 
Also the instances of hypergama-globulinemia was not associated 
with overt evidence of hepatic involvement, infection or increased 
numbers of plasma cells in bone marrow. Waldmann et.al. (24) studied 
albumin metabolism in patients with lymphoma. His evidence con¬ 
curred with that of others (25) suggesting that hypoalbuminemia 
was secondary to diminished albumin synthesis. Deficient caloric 
intake, malabsorption, liver damage, nitrogen trapping by the 
tumor have all been speculated as causes of the protein abnormalities. 
But in many of the patients studied these abnormalities couldn't 
fully explain the deficiency seen nor has anyone to date been able 
to adequately explain the specific etiology of the serum protein 
abnormalities. 
No one has ever specifically investigated serum protein ab¬ 
normalities in patients with documented biopsy-proven liver in¬ 
volvement with Hodgkin's disease. In this study 78% of patients 
with liver involvement had hypoalbuminemia and hyperglobulinemai. 
Some patients demonstrated elevated levels of alpha^, alpha2 or 
gammaglobulin. No patients among the control had protein abnor¬ 
malities. This difference is statistically significant. The con¬ 
trol patients had approximately as extensive tumor loads. Thus 
negating factors dependent on this as causes of protein abnormal-- 
ities, for example, nitrogen trapping, severe systemic symptoms, and 
decreased caloric input. This data suggests that perhaps liver 
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disease may be the cause of serum protein abnormalities in the 
majority of instances of Hodgkin's disease. There is no instance 
of serum protein abnormality without positive liver function tests 
although the inverse is true. Consequently, protein profiles don't 
seem to be a more sensitive indicator of liver involvement than 
routine LFT's. On the other hand in comparison with the results 
of LFT's among controls, protein profiles may be a more specific 
indicator of liver involvement. 
Anemia is the most serious initial hemotological abnormality 
found among Hodgkin's patients. It usually occurs during the later 
phases of advanced disease. As shown in Tables 9 and 9a, anemia 
was present in 66% of patients with liver involvement at presen¬ 
tation while 33% of control patients viere anemic. This difference 
was not statistically significant. Among patients with liver in¬ 
volvement three had a hypochronic, microcytic anemia while five 
had a normochronic,normocytic anemia. In no patients were there 
evidence of blood loss, or a hemolytic process. Although the 
cause of the anemias were not made clear by this study, it appears 
that liver involvement doesn't add significantly to the incidence 
of anemia in Hodgkin's disease. Rather the anemias are probably 
secondary to advanced disease. The hypochronic, microcytic anemias 
were probably secondary to chronic disease. Since four of five 
patients with liver involvement and normochronic, normocytic anemias 
also had positive bone marrow biopsies, it is speculated that perhaps 
the cause of this anemia is bone marrow invasion with neoplasia. 
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One would suspect that patients with liver involvement might do 
poorly secondary to major organ disease. As shown in Tables 10 and 
11, half of the patients in the study group died of their disease 
while none of the control patients demised. This difference is 
statistically significant (p<_.0001). As Table 11 indicates age 
doesn't appear to have a significant effect on survival. Referring 
to the survival curve (Figure 3) and Table 12 it is worth noting 
that of the five liver patients that died within one year after their 
diagnosis, three achieved no response from chemotherapy and the re¬ 
maining two achieved only partial remission. None were salvaged by 
radiation and all died with this disease. Of the remaining three 
patients that survived between one and five years after their diag¬ 
nosis, two had only partial responses to chemotherapy and also died 
with their disease. The remaining patient had a complete response 
to chemotherapy and is currently alive without evidence of Hodgkin's 
disease. 
Of the four patients in the combined modality Yale protocol with 
liver involvement who have survived ten years or greater without evi¬ 
dence of Hodgkin's disease, all had complete responses to chemotherapy 
initially. None had irradiation site failures except one who had a 
relapse in the mediastinum which responded to cycles 4 and 5 of chemo¬ 
therapy. 
Regarding age, sex, histology, and general state of health prior 
to diagnosis there didn't appear to be anything distinctive among 
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